Table. 3. Cell viability assays employed in the evaluation of drug efficacy using MCTs
From: Challenges of applying multicellular tumor spheroids in preclinical phase
Assay type | Culture model | Cancer cell | Drugs | Readout | References |
|---|---|---|---|---|---|
CellEvent Caspase-3/7 Green | 2D | Prostate cancer (VCaP, LNCaP) | MLN4924 | Spheroid | [107] |
LysoTracker Deep Red | 2D | Prostate cancer (VCaP, LNCaP) | MLN4924 | Spheroid | [109] |
Annexin V-APC | 2D | Breast cancer (MDA-MB-435S, MDAMB-468, MDA-MB-231, SK-BR-3) | – | Disassociation | [22] |
MTT | 2D | Breast cancer (MCF-7) | Tamoxifen | Disassociation | [97] |
LDH | 2D | Breast cancer (MCF-7) | Tamoxifen | Disassociation | [97] |
AlamarBlue | 2D | Lung cancer (H460, A549, H1650) | Cisplatin, Gemcitabine 5-fluorouracil, Camptothecin | Disassociation | [59] |
2D | Breast cancer (MCF-7) | Doxorubicin | Spheroid | [69] | |
Live/Dead | 2D | Breast cancer (MCF-7) | Doxorubicin | Spheroid | [110] |
2D | Breast cancer (MCF-7) | – | Spheroid | [73] | |
Cultrex® 3D Colorimetric | 3D | Lung cancer (A549) | 4-HPR-HSA | Spheroid | [106] |
CellTiter-Glo Luminescent | 3D | Glioblastoma (U-87 MG, KNS42) Oral squamous (LICR-LON-HN4) Breast carcinoma (MDA-MB-231) | HSP90 chaperone inhibitor PI3 kinase/mTOR inhibitor PLCg inhibitor | Spheroid | [41] |